Get the Stockscreener App
99.18
0.88%
-0.8675
Incyte Corp stock is traded at $99.18, with a volume of 526.67K.
It is down -0.88% in the last 24 hours and down -7.21% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
See More
Previous Close:
$100.05
Open:
$98.52
24h Volume:
526.67K
Relative Volume:
0.26
Market Cap:
$19.47B
Revenue:
$4.81B
Net Income/Loss:
$1.19B
P/E Ratio:
16.64
EPS:
5.961
Net Cash Flow:
$1.17B
1W Performance:
-3.35%
1M Performance:
-7.21%
6M Performance:
+25.22%
1Y Performance:
+49.50%
1-Day Range:
$97.25
$99.52
1-Week Range:
$97.25
$109.48
52-Week Range:
$53.56
$112.29
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
99.17 | 19.64B | 4.81B | 1.19B | 1.17B | 5.961 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.33 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.91 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
832.87 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.33 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.06 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-26 | Initiated | H.C. Wainwright | Buy |
| Jan-20-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-08-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-03-25 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-01-25 | Initiated | Barclays | Overweight |
| Jun-16-25 | Upgrade | Stifel | Hold → Buy |
| Mar-18-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-17-24 | Initiated | UBS | Neutral |
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
INCY Q4 Deep Dive: Revenue Growth Outpaces Profit as Pipeline Advances, Margins Narrow - Finviz
Incyte Corporation (NASDAQ:INCY) Q4 2025 Earnings Call Transcript - Insider Monkey
INCY: HC Wainwright & Co. Reiterates Buy Rating, Maintains $135 Price Target | INCY Stock News - GuruFocus
Incyte Faces Growing Pains As It Looks To Build Post-Jakafi Foundation - Citeline News & Insights
Incyte Faces Jakafi Patent Cliff; Focus on Opzelura and Advancing Pipeline to Offset Losses - Morningstar
Decoding Incyte Corp (INCY): A Strategic SWOT Insight - GuruFocus
Incyte (INCY) Shares Fall After Q4 Earnings Miss and Weak 2026 O - GuruFocus
Incyte Corporation Reports Strong 2025 Fiscal Results and Provides 2026 Guidance - AlphaStreet News
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte (INCY) Reports Strong Q4 and Annual Revenue Growth - GuruFocus
Incyte Corp (INCY) Q4 2025 Earnings Call Highlights: Strong Reve - GuruFocus
Incyte (INCY) Shares Fall After Q4 Earnings Miss and Weak 2026 Outlook - GuruFocus
Jefferies reiterates Buy rating on Incyte stock, maintains $120 price target - Investing.com
Why Incyte (INCY) Stock Is Nosediving - Finviz
INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales - Finviz
Incyte (INCY) Releases Product Revenue and Expense Guidance for 2026 - GuruFocus
Truist Securities reiterates Hold rating on Incyte stock, maintains $103 target - Investing.com
Incyte Q4 2025 slides: Revenue surges 28%, stock dips on EPS miss - Investing.com
Incyte (INCY) Faces Challenges with Opzelura as Jakafi Patent Expiry Looms - GuruFocus
Earnings call transcript: Incyte’s Q4 2025 revenue beats estimates, stock dips - Investing.com
Incyte (NASDAQ:INCY) Posts Quarterly Earnings Results, Misses Estimates By $0.16 EPS - MarketBeat
Incyte (NASDAQ:INCY) Surprises With Q4 CY2025 Sales - Finviz
Incyte Corp. (NASDAQ:INCY) Reports Mixed Q4 2025 Results with Revenue Beat and EPS Miss - Chartmill
Incyte weak 2026 revenue forecast heightens Jakafi patent concerns - Reuters
Incyte: Q4 Earnings Snapshot - kens5.com
Incyte (INCY) Q4 Revenue Surpasses Estimates Despite EPS Miss - GuruFocus
Incyte (INCY) Q4 2025 Earnings Call Transcript - The Globe and Mail
Incyte shares fall as Q4 earnings miss overshadows revenue beat - Investing.com
Incyte shares fall as Q4 earnings miss overshadows revenue beat By Investing.com - Investing.com South Africa
Incyte earnings missed by $0.11, revenue topped estimates - Investing.com
Incyte earnings missed by $0.11, revenue topped estimates By Investing.com - Investing.com South Africa
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
Earnings Breakdown: Incyte Q4 - Benzinga
Why Incyte (NASDAQ:INCY) Appears in Nasdaq Composite Index Coverage? - Kalkine Media
A Look Ahead: Incyte's Earnings Forecast - Benzinga
Incyte earnings up next: Can pipeline ease Jakafi reliance? - Investing.com
Incyte (INCY) Q4 Earnings: What To Expect - Finviz
Piper Sandler Raises Incyte (INCY) Price Target to $110 | INCY S - GuruFocus
Incyte sets February 10 call to unveil Q4 and full-year 2025 results - MSN
Incyte Gears Up to Report Q4 Earnings: Is a Beat in the Cards? - Finviz
How Investors Are Reacting To Incyte (INCY) EMA Backing For Zynyz Combo In First-Line Anal Cancer - simplywall.st
Incyte’s Zynyz Wins CHMP Backing And Opens New EU Opportunity - simplywall.st
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday - Benzinga
Incyte (INCY) Receives New "Buy" Rating and Price Target of $135 - GuruFocus
Incyte’s Transition From A Jakafi Company To A More Diversified Pharma - Citeline News & Insights
A Glimpse Into The Expert Outlook On Incyte Through 8 Analysts - Benzinga
Barclays Maintains Overweight Rating on INCY, Raises Price Targe - GuruFocus
TD Cowen Keeps Buy Rating on Incyte (INCY), Cites Roadmap to Triple Non-Jakafi Revenue by 2029 - Finviz
Analysts differ in opinion on Jakafi drug maker Incyte (INCY) - MSN
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
Prelude climbs as FDA clears study for Incyte-partnered cancer candidate - Seeking Alpha
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Incyte Corp Stock (INCY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Issa Mohamed Khairie | EVP, Head of US Oncology |
Jan 07 '26 |
Sale |
109.07 |
10,856 |
1,184,064 |
66,132 |
| Stein Steven H | EVP & Chief Medical Officer |
Jan 05 '26 |
Sale |
101.70 |
15,634 |
1,589,978 |
34,203 |
1.87%
3.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):